35 results
6-K
TAK
Takeda Pharmaceutical Co
2 Feb 24
Current report (foreign)
6:16am
arising from differences between the fixed prices and floating market prices of renewable energy in a virtual power purchase agreement and those … method. The key assumptions taken into account include forecasted renewable energy prices and the expected generation of the renewable energy
6-K
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:18am
in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions; and other factors identified in Takeda’s most
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
1 Feb 24
Current report (foreign)
6:06am
energy conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas
6-K
EX-99.1
TAK
Takeda Pharmaceutical Co
30 Nov 23
Current report (foreign)
6:01am
conservation measures and future advancements in renewable energy or low carbon energy technology will enable us to reduce our greenhouse gas emissions
6-K
TAK
Takeda Pharmaceutical Co
30 Oct 23
Current report (foreign)
6:02am
in connection with settlements of cash flows arising from differences between the fixed prices and floating market prices of renewable energy in a virtual … is measured using the discounted cash flow method. The key assumptions taken into account include forecasted renewable energy prices and the expected
6-K
EX-99.1
9mbcv9eucdjkum44au
30 Oct 23
Current report (foreign)
6:02am
6-K
EX-99.1
l36dpuedb52w
26 Oct 23
Current report (foreign)
6:20am
6-K
reqi apfhyd
1 Aug 23
Current report (foreign)
6:10am
6-K
EX-99.1
mt9m9 1c9hi4f
27 Jul 23
Current report (foreign)
6:05am
6-K
EX-99.1
a7xay4 b39
6 Jul 23
Current report (foreign)
6:18am
6-K
EX-99.1
bn2jh 26d
23 Jun 23
Current report (foreign)
6:13am
6-K
EX-99.1
3uajowyk
30 May 23
Current report (foreign)
6:19am
6-K
EX-99.1
urpi1he0zu
30 May 23
Current report (foreign)
6:14am
6-K
EX-99.1
qn7l01 g26
30 May 23
Current report (foreign)
6:11am
6-K
e0v3csxg
11 May 23
Current report (foreign)
6:07am
6-K
EX-99.1
k6vauj
11 May 23
Current report (foreign)
6:07am
6-K
q59nll9
13 Dec 22
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
7:00am
6-K
EX-99.1
o2tlc 2b4ld
30 Nov 22
Current report (foreign)
6:28am
6-K
EX-99.1
qowha
27 Oct 22
Current report (foreign)
6:01am